Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P43405
UPID:
KSYK_HUMAN
Alternative names:
Spleen tyrosine kinase; p72-Syk
Alternative UPACC:
P43405
Background:
Tyrosine-protein kinase SYK, also known as spleen tyrosine kinase and p72-Syk, plays a pivotal role in immune response regulation. It mediates signal transduction from various transmembrane receptors, influencing innate and adaptive immunity, cell adhesion, and vascular development. SYK's activation is crucial for B-cell maturation, T-cell receptor signaling, and the innate immune response to pathogens, highlighting its broad impact on cellular functions.
Therapeutic significance:
Given its involvement in Immunodeficiency 82 with systemic inflammation, a disorder marked by recurrent infections and multi-organ inflammation, targeting SYK offers a promising therapeutic strategy. Its role in immune response modulation and disease pathogenesis underscores the potential for SYK inhibitors in treating inflammatory and autoimmune diseases.